Mentioned in ?
References in periodicals archive ?
AMSTERDAM, June 17 /PRNewswire/ -- Bristol-Myers Squibb Company today presented interim data from a randomised Phase II study of the investigational compound dasatinib (140 mg/day) or imatinib (800 mg/day) in patients with chronic-phase chronic myelogenous leukaemia (CML) resistant to imatinib (less than or equal to 600 mg/day).
To address this need, pharmaceutical companies have developed several first-in-class molecules for the treatment of Ewing's Sarcoma, such as Yondelis, Zalypsis, sunitinib (Sutent), dasatinib (Sprycel), ganitumab and cixutumumab.
A Pivotal Phase II Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial [Abstract 163]
Bristol-Myers Squibb presented results from four single-arm, open-label Phase II studies of dasatinib - an oral, investigational compound.
The addition of nilotinib (Tasigna([R]), Novartis Oncology) and dasatinib (SPRYCEL([R]), Bristol-Myers Squibb) as primary treatment options for patients with CML are the most significant updates to the NCCN Guidelines for CML, noted Dr.
An analogous mutation (T315I) in the BCR-ABL fusion kinase in chronic myelogenous leukemia cells renders them resistant to ABL kinase inhibitors, gleevec and dasatinib.
BOSTON -- Patients with chronic myeloid leukemia (CML) who were treated with nilotinib are found to be associated with better treatment adherence, less hospitalizations, and lower total health care costs than patients treated with dasatinib, according to a new study released by Analysis Group Inc.
Investigators also showed that the leukemia cells were sensitive to several targeted therapeutic agents, imatinib and dasatinib, which are already being used against other leukemias, but not this subtype.
Major cytogenetic response (MCyR) rate of 33% in patients who had failed 2 TKIs - these patients failed imatinib and were also resistant to dasatinib or nilotinib
In January, 2013, Ministry of Health & Family Welfare forwarded to this Department, minutes of the meeting of the Committee set up under that Ministry for invoking provisions of Compulsory Licensing of Drugs in India in which it was recommended to put three drugs namely Herceptin, Dasatinib and Lxabepilone under Compulsory Licensing as per the provisions of Section 92 of the Patents Act, 1970.
Arnon Nagler, director of hematology at Sheba Medical Center, said "Iclusig is a very effective treatment option with utmost importance to CML or Ph+ALL patients who are resistant to dasatinib or nilotinib and for those patients with the T315I BCR-ABL mutation.
and Europe of dasatinib for the treatment of chronic myelogenous leukemia.